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M I C R O B I O L O G Y
Mapping of host-parasite-microbiome interactions 
reveals metabolic determinants of tropism 
and tolerance in Chagas disease
E. Hossain1,2, S. Khanam2,3, D. A. Dean1,2, C. Wu1,2, S. Lostracco-Johnson4, D. Thomas4, 
S. S. Kane1,2, A. R. Parab2,3, K. Flores2,5, M. Katemauswa1,2, C. Gosmanov1,2, S. E. Hayes1, 
Y. Zhang1, D. Li6, C. Woelfel-Monsivais2,3, K. Sankaranarayanan2,3*, L.-I. McCall1,2,3*
Chagas disease (CD) is a parasitic disease caused by Trypanosoma cruzi protozoa, presenting with cardiomyopathy, 
megaesophagus, and/or megacolon. To determine the mechanisms of gastrointestinal (GI) CD tissue tropism, we 
systematically characterized the spatial localization of infection-induced metabolic and microbiome alterations, 
in a mouse model of CD. Notably, the impact of the transition between acute and persistent infection differed 
between tissue sites, with sustained large-scale effects of infection in the esophagus and large intestine, provid-
ing a potential mechanism for the tropism of CD within the GI tract. Infection affected acylcarnitine metabolism; 
carnitine supplementation prevented acute-stage CD mortality without affecting parasite burden by mitigating 
infection-induced metabolic disturbances and reducing cardiac strain. Overall, results identified a previously- 
unknown mechanism of disease tolerance in CD, with potential for new therapeutic regimen development. More 
broadly, results highlight the potential of spatially resolved metabolomics to provide insight into disease patho-
genesis and infectious disease drug development.
INTRODUCTION
Chagas disease (CD), also known as American trypanosomiasis, is a 
neglected tropical disease endemic in Latin America. However, 
because of migration, CD now has a global reach spanning North 
America, Europe, and Asia. CD is caused by infection with the 
protozoan parasite Trypanosoma cruzi. Six to 8 million people are 
infected with T. cruzi, with approximately 12,000 deaths per year. 
Infected individuals pass first through an acute disease stage, usually 
asymptomatic, and then to a chronic asymptomatic (indeterminate) 
stage that can last for decades. Thirty to 40% of infected individuals 
progress from indeterminate to determinate (symptomatic) chronic 
CD, 20 to 30% with cardiovascular complications (heart failure, 
arrhythmias, and thromboembolism) and 10 to 15% with gastro-
intestinal (GI) symptoms (megaesophagus and megacolon) (1). 
Digestive CD has been neglected compared to cardiac CD and is 
consequently much more poorly understood. However, recent studies 
using bioluminescent parasites in mouse models have shown that 
specific sites in the GI tract are parasite reservoirs in chronic CD 
and may be major contributors to cardiac symptom development, 
particularly after treatment failure (2, 3). Treatment of GI CD is also 
challenging, with limited options once symptoms become apparent 
(1). There is, therefore, a strong need to improve our understanding 
of the interaction between T. cruzi and the GI tract, both to clarify 
mechanisms of GI CD pathogenesis and to define GI factors con-
tributing to cardiac CD, leading to new treatment strategies.
The GI tract is a complex environment where host, pathogen, and 
microbiota interact to affect disease pathogenesis. We previously 
demonstrated that T. cruzi infection affects the fecal microbiome and 
metabolome (4), but information on the specific GI sites driving this 
output had not yet been determined. In this study, we integrated small 
molecule–focused liquid chromatography–tandem mass spectrometry 
(LC-MS/MS) and spatial metabolite mapping (“chemical cartography”), 
in conjunction with microbiome analysis, to systematically charac-
terize the T. cruzi–induced changes in the GI microenvironment in 
acute and persistent, long-term, experimental T. cruzi infection. We 
specifically focused on small-molecule characterization because small 
molecules represent the output of cellular processes as well as their 
regulators and therefore have the closest relationship to phenotype 
(5). Given that most drugs are still small molecule–based, we further 
hypothesized that identifying infection-associated disturbances in 
the small-molecule profile can most rapidly lead to new treatments 
for CD.
Results identified organ-specific and organ subsite–specific 
disruptions in the chemical and microbial GI environment by T. cruzi 
and highlighted differential mechanisms of transition from acute to 
persistent, long-term infection depending on the organ. These 
results provide a mechanism by which consistent perturbations of 
tissue biochemical pathways lead to GI CD pathology in the esoph-
agus and large intestine. Consistent infection-induced elevation of 
acylcarnitine family members across organs further led us to investigate 
the role of acylcarnitines in disease pathogenesis. Supplementing 
animal drinking water with carnitine prevented acute-stage mortality 
in experimental CD in the absence of antiparasitic effect, revealing 
a previously-unknown mechanism of disease tolerance in CD, via re-
setting of host metabolism back toward a metabolic profile similar to 
uninfected animals. Overall, these results identified previously- unknown 
mechanisms of CD pathogenesis, with major translational applications 
to CD drug development. Furthermore, the data collected here on 
uninfected animals, and our approach in general, can serve as a 
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reference to investigate determinants of pathogen tropism and nov-
el treatment strategies for any other GI pathogen.
RESULTS
Regiospecific molecular impact of T. cruzi colonization 
in the GI tract
GI CD is still poorly understood. In our prior work, we identified 
specific small molecules correlated with cardiac parasite tropism 
(6). Here, we sought to identify the local tissue chemical changes 
associated with parasite GI colonization. Mice were infected with 
1000 luciferase-expressing T. cruzi strain CL Brener parasites [strain 
generated and provided by J. Kelly, London School of Hygiene & 
Tropical Medicine (3)]. Twelve days (acute stage) and 89 days after 
infection (persistent, long-term infection), animals were euthanized, 
the GI tract was sectioned, and parasite burden in each section was 
determined by ex vivo bioluminescence imaging (Fig. 1, A to C, and 
fig. S1). At 12 days after infection, parasite burden was high through-
out the GI tract, except in the cecum, where the parasite burden was 
significantly lower than in the esophagus (Kruskal-Wallis P < 0.05 
for impact of sampling position on parasite burden and Dunn’s post 
hoc test with Bonferroni correction, P = 0.0075), in the distal small 
intestine (positions 8 and 9, Dunn’s post hoc test with Bonferroni 
correction, P = 0.0037 and P = 0.0052, respectively), and in the 
distal large intestine (positions 12 and 13, Dunn’s post hoc test with 
Bonferroni correction, P = 0.0032 and P = 0.0014, respectively; 
Fig. 1, A and B). At 89 days after infection, the parasite burden was 
significantly higher in the cecum and in parts of the large intestine 
than in the small intestine (Kruskal-Wallis P < 0.05 for impact of 
sampling position on parasite burden and Dunn’s post hoc test with 
Bonferroni correction, P = 0.00037, P = 0.0034, and P = 0.0086, 
for positions 10, 11, and 12 compared to position 5, respectively; 
P = 0.0055 and P = 0.036 for positions 10 and 11 compared to position 
6, respectively; and P = 0.0016, P = 0.013, and P = 0.030 for positions 
10, 11, and 12 compared to position 7, respectively; Fig. 1, A and C). 
In general, as expected, parasite burden decreased from 12 to 89 days 
after infection. However, unexpectedly, parasite burden increased 
in the cecum during the transition from acute to persistent disease, 
suggesting a possible role for the cecum as a parasite reservoir pro-
tected from antiparasitic immune responses (Fig. 1, A to C). These 
observations indicate that all GI sites can initially harbor T. cruzi 
but then differentially respond to parasite presence, leading to the 
ability of the parasite to persist in some sites but not others.
Given this differential parasite tropism in persistent infection 
and the unique aspects of CD pathology, we sought to investigate 
the molecular determinants of parasite persistence versus disease 
resolution. To do so, we extracted small molecules (metabolites) 
from each collected GI section and analyzed these molecules by LC-
MS/MS in positive and in negative mode. As expected, the strongest 
determinant of overall chemical profile was the source organ and 
sample position within that organ, as observed by principal coordinate 
analysis (PCoA; Fig. 1D). In PCoA analysis, each sample is rep-
resented as a sphere in three-dimensional (3D) space, with spheres 
close together indicating samples with similar metabolite composi-
tion. Statistical significance of PCoA clustering was evaluated using 
permutational multivariate analysis of variance (PERMANOVA), 
with PERMANOVA P value <0.05 indicating statistical significance 
and PERMANOVA R2 indicating the percentage of chemical variation 
that is explained by specified metadata variables. Sampling position 
and source organ thus had a significant impact on the tissue 
metabolite composition [PERMANOVA based on sampling position, 
P < 0.001, R2 = 12.067% (all time points combined); PERMANOVA 
based on source organ, P < 0.001, R2 = 39.951% (all time points 
combined)]. In contrast, PERMANOVA analyses based on infection 
status had lower R2 values, indicating the absence of organism-wide 
shifts in metabolite composition in response to infection (12 days 
after infection, P = 0.019, R2 = 1.011% and 89 days after infection, 
P = 0.014, R2 = 0.982%; both time points combined, P = 0.008, 
R2 = 0.598%). Comparison of chemical families differentially modulated 
by infection also identified few commonalities between sample sites 
(fig. S2). We therefore focused our analysis on the impact of infec-
tion in each individual organ.
Visualization of the chemical profile in each organ in relation-
ship to infection status using PCoA analysis revealed organ-specific 
differences in the impact of T. cruzi infection. Acute-stage infection was 
associated with major disturbances in the overall esophagus chemical 
profile (PERMANOVA P = 0.002, R2 = 15.871%), with lower-scale 
perturbations in the small intestine and cecum (PERMANOVA 
P < 0.001, R2 = 6.95% and PERMANOVA P = 0.02, R2 = 10.411%, 
respectively) (Fig. 1E). The strongest acute-stage disruption within 
the small intestine chemical environment was observed in the distal 
small intestine, where parasite burden is the highest (PERMANOVA 
P < 0.001, R2 = 30.198%; P < 0.001, R2 = 26.063; and P = 0.006, 
R2 = 12.564, for sampling positions 7, 8, and 9, respectively; Fig. 1J). 
Metabolic disruptions that had been observed in the acute stage 
resolved by 89 days after infection for the cecum (PERMANOVA 
P = 0.17, R2 = 6.955%), decreased in magnitude for the small intestine 
(PERMANOVA P < 0.001, R2 = 4.824), became apparent in the 
stomach and large intestine (PERMANOVA P = 0.021, R2 = 4.429% 
and PERMANOVA P = 0.008, R2 = 6.323%, respectively), and 
increased in magnitude in the esophagus (PERMANOVA P < 0.001, 
R2 = 38.061%; Fig. 1, E to I). The largest statistically significant sites 
of metabolome disturbance in later disease stages were the esophagus 
and large intestine, which are the sites of damage in symptomatic 
human chronic-stage GI CD (1). On a per-sampling site basis, spatial 
heterogeneity in terms of overall effect size (R2) was observed with-
in a given organ. The largest increase in R2 during the transition 
from acute to persistent infection was observed in the esophagus, 
distal stomach, and central large intestine (2.4-, 2.0-, and 1.9-fold 
increases, respectively; Fig. 1J).
Next, we investigated the nature of the specific metabolic changes 
associated with these infection-altered overall chemical profiles. 
Feature annotation rates were considerably higher in positive mode 
than in negative mode (35.4 versus 10.2%), so we focused this anal-
ysis on positive mode LC-MS/MS data. We used machine learning 
(random forest) approaches to identify specific molecular features 
driving the differences between infected and uninfected tissues. 
Given our observations on the impact of sampling position on 
metabolite features (PCoA; Fig. 1D), these comparisons were inde-
pendently performed for each organ. In the acute stage, we observed 
elevation in specific acylcarnitines and specific phosphatidylcholine 
(PC) family members in the different organs (Fig. 2, A to F; data file 
S1; and fig. S3). We also observed elevation in kynurenine in the 
stomach and large intestine in the acute stage. These differences 
continued at 89 days after infection for the proximal and central 
large intestine only (Fig. 2, G and H; data file S1; and fig. S3). Notably, 
the levels of tryptophan, the precursor of kynurenine, were corre-
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Fig. 1. Spatial impact of T. cruzi infection is reflected by spatial modulation of the tissue small-molecule profile. C3H/HeJ male mice (n = 5 per group and replicate) 
were mock-infected or infected with 1000 luminescent T. cruzi strain CL Brener trypomastigotes in two biological replicates. GI samples were collected 12 and 89 days 
after infection. (A) Parasite burden at each sampling site. To correct for variations in sample size and background signal, luminescence counts were normalized to signal 
from matched uninfected samples and to sample weight, for each sampling position. (B and C) Median normalized luminescent signal, at each sampling site, 12 days 
after infection (B) and 89 days after infection (C). Common logarithmic scale for (B) and (C), scaled from lowest luminescent signal (dark blue) to highest signal (dark red). 
(D) PCoA analysis showing separation between sampling sites in terms of overall chemical composition, even within a given organ (positive mode, all time points com-
bined, Bray-Curtis-Faith distance metric). (E to I) PCoA analysis showing chemical composition differences (positive mode analysis) between infected and uninfected 
samples in the esophagus (E), stomach (F), small intestine (G), cecum (H), and large intestine (I). (J) R2 at each sampling site [common logarithmic scale, scaled from lowest 
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sites where kynurenine was elevated, whereas it was increased by 
infection in persistent infection in the esophagus (Fig. 2, I and J). 
Kynurenine is induced by inflammation; kynurenine metabolites 
have direct antiparasitic effects and contribute to the control of 
acute T. cruzi infection (7). However, they can also induce regulatory 
T cells (7), and hence, our observation of continued kynurenine 
elevation at later time points in the large intestine may contribute 
to parasite persistence in this organ. In accordance with our prior 
observations in the context of the fecal metabolome (4), specific 
large intestine and small intestine bile acid derivatives were in-
creased in infected mice at 12 days after infection (Fig. 2, K and M; 
data file S1; and fig. S3). At 89 days after infection, molecular features 
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Fig. 2. Common and tissue-specific metabolic changes identified by random forest demonstrate persistence of these alterations at sites of CD. (A to C) Infection-induced 
elevation of C20:4 acylcarnitine in the esophagus and small intestine in the acute stage, persisting in the esophagus in the later infection stage. (D to F) Infection-induced 
elevation of PC(20:4) in the esophagus and large intestine in the acute stage, persisting in the esophagus 89 days after infection. PC(20:4) was decreased in the acute stage 
in the infected small intestine. (G and H) Infection-induced elevation of kynurenine in stomach and large intestine in the acute stage, persisting in the large intestine 
89 days after infection. (I and J) Infection-induced decrease in tryptophan at sites of increased kynurenine in the large intestine (12 and 89 days after infection). Infection also 
increased tryptophan in the esophagus 89 days after infection. (K to M) Infection-induced increase in the small intestine, cecum, and large intestine cholic acid (all detected 
adducts combined), acute stage only. E, esophagus; SC, stomach; SI, small intestine; C, cecum; LI, large intestine. Black lines in  (A and B), (D and E), and (G to L) indicate 
false discovery rate (FDR)–corrected Mann-Whitney P < 0.05. Spatial distribution plots in (C), (F), and (M) are scaled for each specified metabolite, from lowest median 
normalized metabolite abundance (dark blue) to highest abundance (dark red). Linear scale in (C) and (F) and logarithmic scale in (M). Asterisks (*) above GI tract positions 
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identified as elevated by infection include specific acylcarnitines 
(e.g., C20:4 acylcarnitine in the esophagus), specific PCs [e.g., 
PC(22:5), PC(20:4), and PC(22:6) in the esophagus and PC(22:4) in 
the large intestine], specific amino acids, and derivatives (e.g., 
kynurenine in the large intestine and tryptophan in the esophagus) 
(Fig. 2, B  to J; data file S1; and fig. S3). The pattern of resolution 
versus persistence of these metabolic changes reflected known sites 
of CD: For example, most of the top 10 metabolic perturbations 
observed in the acute stage in the esophagus were still perturbed 
89 days after infection, whereas all the small intestine acute-stage 
perturbations were resolved in later disease stages (Fig. 2 and data 
file S1). Lysophosphatidylcholines (LPCs), in particular, increase 
T. cruzi invasion and inflammatory cell recruitment while inhibiting 
antiparasitic nitric oxide production (8). Thus, the sustained PC 
elevation observed in the esophagus and large intestine may con-
tribute to CD progression in those organs. Overall, these results 
identified tissue metabolic changes linked to GI infection distribu-
tion and to sites of CD in the GI tract, as well as several metabolic 
pathways correlated with infection status.
Durable effect of T. cruzi colonization on the  
GI tract microbiome
Several of the molecules identified in our dataset are of microbial 
origin or are microbially modified, such as indole-l-lactate, indoxyl 
sulfate, and secondary bile acids. Studies comparing germ-free and 
colonized mice have also shown that the microbiota influences a 
variety of the metabolites detected in our study, including bile acids, 
tryptophan, tyrosine, and maltotriose (9, 10). Tryptophan and tyro-
sine, in particular, were affected by infection [tryptophan: decreased 
in the large intestine overall, Mann-Whitney P = 6.8 × 10−6 (12 days 
after infection) and P = 0.0043 (89 days after infection); tyrosine: 
decreased in the large intestine overall, Mann-Whitney P = 0.015 
(acute stage), nonsignificant (89 days after infection)]. We have 
previously demonstrated that experimental T. cruzi infection alters 
the fecal microbiome and metabolome (4), a finding that was re-
cently confirmed in T. cruzi–infected children in Bolivia (11). We 
therefore sought to evaluate the spatial impact of T. cruzi infection 
on the microbiota at each collection site in acute-stage disease 
(except for the esophagus where insufficient material was available 
to perform both metabolomic and 16S analyses) and focusing on 
the cecum and large intestine in persistent infection, given their role 
as major sites of CD pathogenesis and the unique metabolomic 
pattern observed at these sites (Fig. 1, H to J).
Differences in the overall microbiota composition (beta diversity, 
all sites combined for a given organ) were observed in the stomach 
and large intestine in the acute stage (PERMANOVA P = 0.05, 
R2 = 3.22% and PERMANOVA P = 0.04, R2 = 3.837%, respectively), 
with nonsignificant changes in the small intestine and cecum 
(PERMANOVA P  =  0.069, R2  =  1.791% and PERMANOVA 
P = 0.058, R2 = 10.657%, respectively). These differences increased 
in magnitude for the cecum and large intestine during the transi-
tion from acute to persistent infection (PERMANOVA P = 0.02, 
R2 = 11.556% and PERMANOVA P = 0.002, R2 = 5.83%, respectively) 
(Fig. 3, A to F). Spatial heterogeneity was also observed within an 
organ (Fig. 3G), with the highest disturbances in the microbiota 
found in the proximal large intestine (sampling position 11, 
PERMANOVA P = 0.022, R2 = 12.36% and PERMANOVA 
P = 0.009, R2 = 10.715% for 12 and 89 days after infection, respec-
tively). Sustained disturbances in the large intestine microbiota 
reflect our findings for the large intestine metabolome, while the 
discrepancies between cecal microbiota and metabolome findings 
may reflect sustained luminal rather than tissue alterations. Overall, 
the lack of resolution of microbiota alterations in these sites cor-
relates well with our observation of continued alterations of the 
fecal microbiota and metabolome through early and persistent ex-
perimental T. cruzi infection (4). In accordance with prior reports 
(4, 11), no significant differences in microbial community richness 
were observed (fig. S4) between infected and uninfected samples at 
12 and 89 days after infection. The effect size (R2) of infection on the 
overall microbiota composition was lower than for our tissue 
metabolomics analysis, suggesting a stronger impact of infection on 
the tissue metabolome than on the microbiota, although, in both 
cases, the proximal large intestine was one of the major sites of 
infection-associated perturbation. This may reflect segregation of 
the microbiome from the site of infection (12) so that only indirect 
effects can be observed. Furthermore, cage and batch effects were 
found to have a larger impact on microbiome composition, while 
metabolome analysis was more robust to these effects, as we previ-
ously reported (4).
Role of acylcarnitines in CD tolerance
Translating omics findings into novel therapeutic approaches is one 
of the major challenges of this post-genome era. Because we ob-
served larger metabolome than microbiome infection-associated 
perturbations and on the basis of our current observations of 
infection- induced elevation in specific acylcarnitine family members 
and on our prior findings of differential cardiac acylcarnitine distri-
bution and mass range in mild versus severe acute T. cruzi infection 
(6), we focused here on acylcarnitines and the potential of acylcarnitine 
modulation for CD treatment. The acylcarnitine subnetwork (Fig. 4A) 
was manually annotated (table S1), and impacts of infection on 
short-chain (C3-C4), mid-chain (C5-C11), and long-chain (C12 
and greater) acylcarnitines were assessed. While total and short-
chain GI acylcarnitine levels were comparable between infected and 
uninfected animals 12 days after infection (fig. S5, B and C), we 
observed significant elevation in total and short-chain acylcarnitine 
levels at each small intestine site in infected animals [total acylcarnitines: 
false discovery rate (FDR)–corrected Mann-Whitney P  =  0.0054, 
P = 0.00042, P = 7 × 10−5, P = 7 × 10−5, and P = 0.00042 for positions 
5, 6, 7, 8, and 9; short-chain acylcarnitines: FDR-corrected Mann-Whitney 
P = 0.00067, P = 0.00056, P = 0.00014, P = 0.00056, and P = 0.0019 
for positions 5, 6, 7, 8, and 9; fig. S5, D and E]. For long-chain 
acylcarnitines, infection-induced acylcarnitine elevation was re-
stricted to the distal portions of the small intestine (FDR-corrected 
Mann-Whitney P = 0.00014, P = 0.00056, and P = 0.00056 for posi-
tions 7, 8, and 9; Fig. 4, B and C). This difference between total and 
spatially resolved short-chain acylcarnitine levels highlights the 
strength of our chemical cartography approach. Mid-chain (C5 to 
C11) acylcarnitine levels were not significantly different 12 days 
after infection between infected and uninfected animals at any GI 
site (fig. S5F). Acylcarnitine small intestine elevation was no longer 
observed 89 days after infection, except for short-chain acylcarnitines 
in the duodenum (sampling position 5, FDR-corrected Mann-Whitney 
P = 0.025), although other select GI sites showed infection-induced 
increases in acylcarnitines (distal large intestine: total acylcarnitines 
and short-chain acylcarnitines, FDR-corrected Mann-Whitney 
P = 0.02 and P = 0.039, respectively; esophagus: short-chain acylcarnitines, 
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was also elevated in select sites 12 days after infection [FDR-corrected 
Mann-Whitney P  =  0.022, P  =  0.0034, P  =  0.00014, P  =  0.00014, 
P = 0.00089, and P = 0.022 for site numbers 4 to 9 (stomach and 
small intestine, 12 days after infection)] but was comparable between 
infected and uninfected tissues at all sites 89 days after infection 
(fig. S5, J and K). In contrast, unmodified carnitine levels were com-
parable throughout the intestine 12 days after infection and only 
significantly elevated in infected esophagus and uninfected central large 
intestine 89 days after infection (FDR-corrected Mann-Whitney 
P = 0.00014 and P = 0. 019, respectively) (fig. S5L).
To determine whether we could translate these findings toward 
novel CD therapeutics and whether these acylcarnitine alterations 
play a causal role in disease progression, we assessed whether carnitine 
supplementation could alter acute CD outcome. Mice were infected 
with either a low dose (5000 trypomastigotes) or a high dose (50,000 
trypomastigotes) of luciferase-expressing CL Brener parasites (n = 5 
per group) (3). At 7 days after infection, animals were distributed 
into two groups of comparable parasite burden and one group 
switched from normal drinking water to drinking water supple-
mented with l-carnitine (equivalent to 100 mg/kg per day based on 
water consumption). Carnitine treatment completely abrogated 
acute CD-induced mortality up to 7 weeks after infection (P = 0.0027 
Mantel-Cox test, 50,000 trypomastigote infection, Fig. 4D; 5000 
trypomastigote infection, fig. S5M) but without any effect on parasite 
burden or parasite distribution (Fig. 4, E and F, and fig. S5N). This 
lack of antiparasitic activity is consistent with prior in vitro high- 
throughput screening data showing no impact of carnitine on parasite 
burden (13). Overall, these results indicate that acylcarnitine modula-
tion by carnitine supplementation can induce disease tolerance in CD.
Given that metabolic adaptations represent major mechanisms 
of disease tolerance (14), to determine the mechanism of action of 
carnitine in acute CD survival, we first sought to determine the 
impact of carnitine supplementation on host metabolism. Plasma 
samples, samples from major CD sites (heart, esophagus, and large 
intestine), and samples from the small intestine [major site of infection- 
induced acylcarnitine perturbation in acute experimental CD; see 
Figs. 2 (A and C) and 4B] were collected from carnitine-treated, 
benznidazole-treated, vehicle control, and uninfected untreated 
animals and analyzed by LC-MS/MS. We observed that carnitine 
treatment “resets” host cardiovascular metabolism in infected 
animals by mitigating infection-induced metabolic perturbations 
in the plasma and the heart: Vehicle-treated animals present with a 
plasma and cardiac metabolite profile distinct from uninfected or 
benznidazole-treated animals, and this distance is reduced in carnitine- 
treated infected animals (plasma: Mann-Whitney P = 0.00059 for 
distance to benznidazole-treated animals and P = 0.004 for distance to 
uninfected animals; heart: Mann-Whitney P = 0.00043 for distance 



























































Fig. 3. T. cruzi infection has a persistent, spatially heterogeneous impact on the microbiota. Representation of between-sample differences in microbial community 
composition through principal coordinate transformation of unweighted UniFrac distances. (A to D) Comparison of acute-stage infected and uninfected samples from 
stomach (A), small intestine (B), cecum (C), and large intestine (D). (E and F) Comparison of cecum (E) and large intestine (F) samples from uninfected and persistently 
infected mice. Spatial heterogeneity was also observed within an organ (G), with the highest disturbances in the microbiota in the proximal large intestine (sampling 
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Fig. 4. Chemical cartography reveals a causal role for carnitine metabolism in acute CD tolerance. (A) Acylcarnitine molecular network (all tissue sites and time 
points combined). (B) Infection-induced increases in acute-stage long-chain acylcarnitines in the distal small intestine (black lines, FDR-corrected Mann-Whitney P < 0.05). 
(C) Spatial distribution of acute-stage long-chain acylcarnitines [medians; common logarithmic scale from lowest (dark blue) to highest abundance (dark red)]. *Above 
sampling sites, P < 0.05 FDR-corrected Mann-Whitney. (D) Carnitine treatment prevents acute-stage mortality (n = 5 per group, 50,000 trypomastigote infection). 
(E and F) Comparable parasite burden between carnitine-treated and vehicle groups. (E) Overall whole-body luminescence. Mean and SEM are displayed. (F) Represen-
tative bioluminescent imaging, week 3 after infection (common scale). (G and H) Carnitine treatment mitigates plasma infection-induced metabolic disturbances (n = 24 
benznidazole and carnitine groups, n = 22 vehicle group, and n = 9 uninfected group). (G) PCoA analysis (Bray-Curtis-Faith distance metric) of plasma samples. (H) Heat 
map showing metabolite features distinguishing vehicle-treated individuals from carnitine-treated, benznidazole-treated, and uninfected individuals (Kruskal-Wallis, 
FDR-corrected P < 0.05). (I) Carnitine treatment mitigates cardiac infection-induced metabolic disturbances. PCoA analysis (Bray-Curtis-Faith distance metric) of heart sam-
ples [n = 5 for uninfected, vehicle, and carnitine groups; n = 4 for benznidazole group (one biological replicate; see fig. S6D for data from second replicate)]. (J) Carnitine 
treatment reduces cardiac Bnp gene expression (n = 10 for benznidazole group and carnitine group, n = 9 for vehicle group, and n = 4 for uninfected group; Student’s 
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uninfected animals; Fig. 4, G and I, and fig. S6, A to D). In contrast, 
carnitine treatment had a much more minor impact on the esopha-
gus and large intestine overall metabolite profile and did not restore 
metabolism in these tissues (Mann-Whitney P > 0.05 for pairwise 
comparisons between carnitine-treated and vehicle-treated animal 
distances to uninfected animals or to benznidazole-treated animals; 
fig. S6, E and F). The impact of carnitine treatment on the abundance 
of most individual heart and plasma metabolite features was, how-
ever, minor (Fig. 4H and fig. S6, H and I), suggesting that the restorative 
effect of carnitine treatment on cardiac and plasma metabolism re-
sults from the sum of multiple small changes on many metabolites 
rather than large alterations in select metabolites. Specific carnitine 
treatment–induced alterations include effects on plasma and heart 
lipids, including plasma PC family members, plasma acylcarnitines, 
and plasma amino acids (Kruskal-Wallis, FDR-corrected P < 0.05; 
Fig. 4H and fig. S6, H and I). Carnitine treatment also increased 
carnitine in the esophagus and small intestine (Mann-Whitney 
P = 0.0079 and P = 0.00037, respectively), acetylcarnitine in the 
small intestine (Mann-Whitney P = 0.00072), short-chain acylcarnitines 
in the small and large intestines (Mann-Whitney P = 0.0029 and 
P = 6.5 × 10−6, respectively), mid-chain acylcarnitines at the heart 
base and in the large intestine (Mann-Whitney P  =  0.043 and 
P = 0.0014, respectively), long-chain acylcarnitines in the large in-
testine (Mann-Whitney P = 2.7 × 10−5), and total acylcarnitines in 
the small and large intestines (Mann-Whitney P = 0.018 and P = 2.7 × 
10−5, respectively) (fig. S7).
In accordance with the lack of effect of carnitine treatment on 
parasite burden, no impact of carnitine treatment on cardiac in-
flammation (fig. S6J) or cardiac cytokine levels were observed (Student’s 
t test P > 0.05 comparing each quantified cardiac cytokine and 
chemokine between carnitine-treated and vehicle-treated animals; 
fig. S6K). As a proximal mechanism of its prosurvival effect, carnitine 
treatment significantly improved cardiac function: Cardiac brain 
natriuretic peptide (BNP) levels were decreased in carnitine-treated 
animals compared to vehicle-treated animals to levels comparable 
to those observed in benznidazole-treated and uninfected animals 
(Student’s t test P = 0.01 comparing carnitine-treated animals to 
vehicle-treated animals; Student’s t test P = 0.27 comparing carnitine- 
treated animals to uninfected animals; and Student’s t test P = 0.5 
comparing carnitine-treated animals to benznidazole-treated animals; 
Fig. 4J). BNP is a biomarker of cardiac strain that is expressed at 
higher levels in the failing heart; reduction in BNP, as observed in 
carnitine-treated animals, indicates reduced myocardial wall stress 
(15). While carnitine can present antioxidant effects (16) and 
antioxidants reduce parasite load (17), given the lack of impact of 
carnitine treatment on parasite load, we consider it unlikely for 
carnitine’s main effect on CD progression to be via antioxidant 
mechanisms. Quantifying cardiac oxidized glutathione, a marker of 
oxidative stress (18), confirmed that carnitine treatment had limited 
impact on the oxidative environment in the heart (Mann-Whitney 
P = 0.558 comparing carnitine-treated and vehicle-treated groups; 
fig. S6L). As expected, oxidized glutathione levels were lower in un-
infected mice than in infected animals (Mann-Whitney P = 0.02062 
comparing infected vehicle-treated and uninfected animals; fig. S6L).
Overall, these findings have important implications for our un-
derstanding of the factors that contribute to the progression from 
asymptomatic to symptomatic CD. Our results further repre-
sent a novel avenue for CD drug development in conjunction with 
antiparasitics to kill T. cruzi.
DISCUSSION
Disease severity is tied to the balance between resistance and tolerance 
mechanisms (14). Resistance reduces pathogen load but can cause 
collateral damage to the host, as has been observed with immune 
clearance of T. cruzi–infected cells (1). In contrast, tolerance reduces 
disease or immune-mediated collateral damage without affecting 
the pathogen load (14). While parasite persistence is required for 
progression to chronic CD, only a minority of infected patients 
progress to symptomatic disease, and parasite load does not fully 
predict disease severity (1). Our results demonstrating that carnitine 
modulation prevented acute-stage mortality without altering parasite 
load (Fig. 4 and fig. S5) provide further evidence for the importance 
of disease tolerance mechanisms in CD. These findings also represent 
the first time that carnitine metabolism has been directly linked to 
disease tolerance mechanisms in infection rather than serving as 
a readout for altered fatty acid metabolism. We determined the 
mechanism by which carnitine supplementation induces disease 
tolerance in CD by demonstrating that it mitigates infection-associated 
host metabolic dysfunction in the circulatory system. Acute T. cruzi 
infection significantly perturbs metabolism across the GI tract and 
circulatory system (Figs. 1 and 4, G and I). Carnitine supplementa-
tion reduced these perturbations in the heart and the plasma 
(Fig. 4, G and I) so that infected carnitine-treated animals become 
metabolically more similar to uninfected or benznidazole-treated 
animals and more dissimilar to infected vehicle-treated controls. 
Pathologic metabolic alterations are known drivers of noninfec-
tious heart failure, and their correction through metabolic modulators 
reduce cardiac stress and improve heart function (19). We observed 
a similar mechanism for carnitine supplementation in acute CD, 
whereby carnitine improved cardiac metabolism, leading to re-
duced cardiac stress (as evidenced by reduced Bnp gene expression; 
Fig. 4J) and thus preventing acute-stage animal mortality. Overall, these 
findings pave the way for future studies of the role of acylcarnitines 
in the progression from asymptomatic to symptomatic CD in 
humans, as well as the development of new interventional strategies 
for CD, most likely in combination with antiparasitic agents to 
ensure complete patient cure and following additional safety and 
efficacy evaluation.
Notably, sites of largest statistically significant and increased overall 
metabolic disturbance in persistent infection were the esophagus and 
large intestine (Fig. 1J), providing a mechanism whereby sustained 
metabolic alterations at these sites drive the marked selective tropism 
of CD for the large intestine and esophagus, even when parasite load is 
low. Select PC family metabolites remained increased in the esophagus 
and large intestine in persistent infection (Fig. 2, D to F). Given the 
proinflammatory role of LPCs (8), this localized elevation in PCs may 
be contributing to the cycles of inflammatory tissue damage that drive 
CD. In contrast, parasite persistence 89 days after infection in the cecum 
was metabolically silent (Fig. 1, H and J), while cecal microbiota re-
mained strongly and significantly affected by infection (Fig. 3E). It 
is tempting to speculate a microbiota-mediated mechanism of re-
duced antiparasitic immune responses in the cecum, perhaps via 
cecal microbiota-derived short-chain fatty acid (20) or induction of 
parasite dormancy at this site (21), leading to the observed parasite 
recrudescence in the cecum following incomplete antiparasitic treatment 
[e.g., (2)]. This awaits further experimentation. In this context, our 
spatial map of infection-induced metabolic changes can serve as a 
reference to begin identifying host and microbiota metabolic signals 
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One limitation of this study is that our methods are not able to 
distinguish between host-derived, microbiota-derived, and T. cruzi– 
derived metabolites. However, given the relative abundance of host 
and microbiota versus parasite metabolites, we anticipate most of 
the detected metabolites to be host or microbiota derived rather 
than parasite derived. Further investigation will also be required to 
determine whether these host metabolite changes are common 
across infection conditions or influenced by T. cruzi virulence. 
While some metabolite changes will likely be unique to a given 
mouse strain and parasite strain combination, mechanisms of CD 
pathogenesis, including parasite-mediated host cell lysis, immune- 
mediated cardiac damage, and subsequent cardiac fibrosis, are 
common across experimental systems and in humans (1). Thus, we 
anticipate many of the metabolic alterations induced by infection in 
our experimental system to be conserved. Many of the changes ob-
served in this study, including increases in long-chain acylcarnitines 
in multiple sites, in kynurenine in the stomach and large intestine, 
and in select PCs in the esophagus and large intestine also match 
data obtained from heart tissue and plasma by Girones et al. (22) in 
BALB/c mice acutely infected with strain Y parasites. Our observed 
decrease in plasma acylcarnitines (remediated by carnitine treatment; 
Fig. 4H) also matches with recent findings that infection decreases 
many acylcarnitines in chronic CD (23). Likewise, several of our 
microbiome observations in this C3H/HeJ mouse model of infec-
tion with luminescent CL Brener parasites [this study and (4)] were 
corroborated in a study of T. cruzi–infected children (11), including 
the following: (i) absence of microbial richness changes associated 
with infection, (ii) infection-associated changes in community composi-
tion (beta diversity), and (iii) alterations in family Lachnospiraceae 
in response to infection.
We observed within-organ spatial heterogeneity in metabolite 
profile (Fig. 1D) and in response to infection at the microbiome 
and metabolome levels (Figs. 1J, 2, and 3G). Acylcarnitines, in par-
ticular, showed strong spatial effects that would have been masked 
by bulk tissue analysis (Figs. 2, A to C, and 4, B and C, and fig. S5). 
Systemic administration of carnitine nevertheless led to localized 
effects, demonstrating the strength and translatability of our 
spatially resolved approach into novel therapeutics. Likewise, the 
protective effects of carnitine supplementation in CD were missed 
by prior in vitro high-throughput screens (13). In vitro treatment 
with carnitine altered the cellular metabolite profile but did not 
restore in vitro infection-induced metabolic changes (fig. S6G), 
indicating that the protective effect of carnitine in CD requires 
the complex in vivo environment. These observations highlight the 
need for a spatial perspective in the study of host-microbe interac-
tions and challenge existing approaches that treat anatomically 
homogeneous tissues as functionally homogenous. They also high-
light the importance of considering in  vivo rather than in  vitro 
host-pathogen metabolic interactions, in a spatial context, for both 
rational drug target discovery and for studies of drug mechanism 
of action. The spatially resolved metabolomic and microbiome 
methods that we illustrate here in experimental T. cruzi infection 
can readily be applied to study other pathogens with specific tissue 
tropism, and we anticipate this approach to have broad applicability. 
Likewise, initial pathogen tropism is affected by tissue characteristics. 
Our comprehensive spatial characterization of the microbiome and 
metabolome of uninfected mice therefore represents a resource that 





No power analyses were performed to predetermine sample size. 
Numbers were selected on the basis of our prior studies showing 
sufficient statistical power achieved with five mice per group (6).
Rules for stopping data collection
Time points for chemical cartography and microbiome analysis 
were predetermined at 12 and 89 days after infection to cover early 
and persistent T. cruzi infection. These time points also enabled 
comparison with our prior analysis of infected cardiac tissues, 
where samples were also collected 12 and 90 days after infection (6), 
and our prior studies of the microbiota in experimental CD, which 
terminated 3 months after infection (4). Prior time course analysis 
had also determined that significant disruptions of the overall fecal 
microbiome and metabolome emerge between 10 and 14 days after 
infection (4). End point for vehicle-treated mice in carnitine efficacy 
studies was based on humane weight loss end points. End point for 
carnitine treatment mechanism of action studies was predeter-
mined to enable sample collection before expected time of death of 
vehicle-treated group in this model.
Data inclusion/exclusion criteria
No inclusion/exclusion criteria were applied in terms of animal 
selection. Samples that showed metabolite profile comparable to 
blanks by PCoA were excluded from subsequent analyses. Sequencing 
data were rarefied to a depth of 5000 reads per individual, established 
after comparing read numbers between blanks and samples.
Outliers
Samples that showed metabolite profile comparable to blanks by PCoA 
were excluded from subsequent analyses. Sequencing samples that 
showed reads <5000 were excluded from the study.
Selection of end points
End points were prospectively determined as described above, except 
for carnitine efficacy studies where humane animal weight loss cutoffs 
(predetermined, weight loss exceeding 20% compared to controls) 
were used.
Replicates
Animal experimentation was performed in biological duplicate. All 
collected GI samples were analyzed in one LC-MS run and in one 
sequencing run. Collected organ and plasma samples from carnitine 
treatment mechanism of action experiments were analyzed in one 
LC-MS run per organ. C2C12 treatment was performed in four 
biological replicates, which were analyzed in a single LC-MS run.
Research objectives
Research objectives were as follows: (i) to determine the spatial 
impact of T. cruzi infection on the microbiome and metabolome 
(predetermined objective), (ii) to determine whether carnitine modu-
lation affects infection severity once this analysis revealed infection- 
associated changes in acylcarnitine profile, and (iii) to determine 
the protolerance mechanism of action of carnitine once carnitine 
treatment showed efficacy in acute disease.
Research subjects or units of investigation
Research subjects are rodents (male C3H/HeJ mice).
Experimental design
Results are derived from controlled laboratory experiments. Male 
C3H/HeJ mice were used for the in vivo studies. The chemical 
cartography and 16S analyses included (i) uninfected mice and 
(ii) infected mice. The carnitine mechanism of action experiments 
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treated with water (vehicle group), (iii) infected and treated with 
benznidazole, and (iv) infected and treated with carnitine. Animal 
weight, survival, and parasite bioluminescence were quantified. Tissues 
and plasma were collected, and microbiome and metabolome com-
position was determined.
Randomization
Animals were initially randomly assigned to either be infected or 
not, on a per-cage basis. For carnitine efficacy experiments, 7 days 
after infection, animals were assigned to either vehicle or carnitine 
group by ensuring that average parasite burden (determined by 
average bioluminescence) was comparable between groups. LC-MS 
run order was random.
Blinding
No blinding was performed.
In vivo experimentation
All vertebrate animal studies were performed in accordance with 
the U.S. Department of Agriculture Animal Welfare Act, the Guide 
for the Care and Use of Laboratory Animals of the National Institutes 
of Health, and all institutional guidelines in specific pathogen–free 
facilities. The protocols were approved by the University of California 
San Diego Institutional Animal Care and Use Committee (protocol 
S14187) and the University of Oklahoma Institutional Animal Care 
and Use Committee (protocol R17-035).
For chemical cartography and 16S analysis, 5-week-old male 
C3H/HeJ mice (the Jackson laboratory) were infected by intraperitoneal 
injection of 1000 red-shifted luciferase-expressing T. cruzi strain CL 
Brener (3) culture-derived trypomastigotes in 100 l of Dulbecco’s 
modified Eagle’s medium (DMEM) (infected group) or mock-infected 
by injection of 100 l of DMEM only (uninfected group). Before 
animal infection, T. cruzi parasites were maintained in coculture 
with C2C12 mouse myoblasts, in DMEM (Invitrogen) supplemented 
by 5% iron-supplemented calf serum (HyClone) and 1% penicillin- 
streptomycin (Invitrogen). Twelve or 89 days after infection, ani-
mals were injected with d-luciferin potassium salt (150 mg/kg; Gold 
Biotechnology) and euthanized by isoflurane overdose followed by 
cervical dislocation. Mice were then immediately perfused with 10 ml 
of ice-cold d-luciferin (0.3 mg/ml) in phosphate-buffered saline (PBS) 
(3) to remove circulating parasites, provide luciferase substrate, and 
prevent quenching of luminescent signal by hemoglobin (24). GI 
organs were collected and sectioned as displayed on Fig.  1B, and 
each section was placed in an individual 96-well plate containing 
ice-cold d-luciferin (0.3 mg/ml) in PBS (3). The plate was imaged in an 
In vivo Imaging System (IVIS) Lumina LT Series III (PerkinElmer), 
and tissues were then immediately snap-frozen in liquid nitrogen, 
followed by storage at −80°C. Tissue section luminescence was 
determined using Living Image 4.5 software, normalized to average 
of uninfected tissue luminescence collected at the same time point 
(replacing negative values with zero) and to tissue weight, and plotted 
in R. Comparisons of luminescent signal between groups were 
performed using a Kruskal-Wallis test with Dunn’s post hoc multi-
ple comparison test, with Bonferroni correction, using R package 
“FSA.” The code is freely available on GitHub (see “Data and materials 
availability” section). Tissue luminescence is linearly related to para-
site load, with a 107-fold difference in luminescence between in-
fected and uninfected tissues ex vivo corresponding to ca. 104 parasite 
equivalents to 50 ng of murine DNA and a 103-fold difference in 
luminescence between infected and uninfected tissues correspond-
ing to ca. 1 parasite equivalents to 50 ng of murine DNA (3). Two 
biological replicate experiments were performed, each including n = 5 
mice for each time point and infection condition (total n = 10 per time 
point and infection condition). The same samples were used as source 
material for 16S and LC-MS analysis (see below), with each tissue site 
from each individual animal representing a single data point in each analysis.
For carnitine supplementation efficacy experiments, mice were 
infected with either a low dose (5000 culture-derived trypomastigotes) 
or a high dose (50,000 culture-derived trypomastigotes) of red-shifted 
luciferase-expressing CL Brener parasites (3). Seven days after in-
fection, mice were injected with d-luciferin potassium salt (150 mg/kg; 
Gold Biotechnology) and imaged (IVIS Lumina LT Series III). Animals 
were allocated to treatment groups to have comparable total body 
luminescence signal between groups. Mice then received l-carnitine 
(VWR) in drinking water ad libitum, normalized to mouse water 
consumptions so that animals received ca. 100 mg/kg per day, or 
regular drinking water (n = 5 per group). Bioluminescent imaging 
was performed weekly. Animals reaching humane end points of 
weight loss >20% were euthanized. Bioluminescence data were ana-
lyzed with Living Image 4.5 software and plotted using GraphPad 
Prism version 8.
For carnitine supplementation mechanism of action experiments, 
mice were infected with 50,000 culture-derived trypomastigotes of 
red-shifted luciferase-expressing CL Brener parasites (3). One group 
of mice was mock-injected with DMEM only (uninfected control group). 
Seven days after infection, mice received benznidazole (100 mg/kg 
per day by intraperitoneal injection in 10% dimethyl sulfoxide vehicle); 
l-carnitine (VWR) in drinking water ad libitum, normalized to mouse 
water consumptions so that animals received ca. 100 mg/kg per day; 
or regular drinking water (two biological replicates for treatment 
groups). Seventeen days after infection, animals were euthanized 
and plasma, heart [sectioned as in (6)], esophagus, small intestine, 
and large intestine collected and sectioned as in Fig. 1B. Tissues 
were either snap-frozen and then stored at −80°C (for LC-MS/MS), 
placed in RNAlater (Sigma-Aldrich) and then stored at −80°C (for 
gene expression analysis), or placed in 10% formalin at room tem-
perature (VWR) and then paraffin-embedded, sectioned and he-
matoxylin and eosin–stained by the University of Oklahoma Health 
Sciences Center, Stephenson Cancer Center Tissue Pathology Shared 
Resource. Histological sections were digitized on a PathScan Enabler 
IV Histology Slide Scanner. For plasma metabolomics, n = 24 for 
benznidazole group and carnitine group, n = 22 for vehicle group 
(both biological replicates combined), and n = 9 for uninfected group. 
For tissue metabolomics, n = 9 for benznidazole group, n = 10 for 
carnitine group and vehicle group (both biological replicates com-
bined), and n = 5 for uninfected group. For Bnp gene expression 
analysis by quantitative reverse transcriptase–polymerase chain reaction 
(qRT-PCR), n = 10 for benznidazole group and carnitine group, 
n = 9 for vehicle group (both biological replicates combined), and 
n = 4 for uninfected group. For fibrosis analysis by qRT-PCR, n = 5 
for benznidazole group, carnitine group, and vehicle group and 
n = 4 for uninfected group (single experiment because no induction 
of fibrosis was observed in infected compared to uninfected animals). 
For histology, n = 5 for benznidazole group, carnitine group, and 
vehicle group (single experiment because no apparent difference 
was observed between carnitine-treated and vehicle-treated animals).
Sample preparation for LC-MS/MS (tissue samples)
Samples from both biological replicate experiments were analyzed 
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using a two-step process, as implemented in our prior work (6), 
normalizing to tissue weight. Tissue samples were homogenized in 
LC-MS–grade water (Fisher Optima): 50 mg of tissue in 125 l of 
water (GI tract analysis, infected versus uninfected samples), 50 mg 
of tissue in 175 l of water (carnitine treatment experiments: small 
intestine and large intestine), and 50 mg of tissue in 250 l of water 
(carnitine treatment experiments: heart tissue and esophagus) using a 
5-mm steel ball in Qiagen TissueLyser at 25 Hz for 3 min. Ten micro-
liters was set aside for DNA extraction and microbiome profile 
analysis from GI samples, except for esophagus where the tissue 
amount was too small, and 100 l was set aside for cytokine analysis 
(heart base only). LC-MS–grade methanol (Fisher Optima) spiked 
with 4 M sulfachloropyridazine (Sigma-Aldrich; all tissue samples) 
and 2 M heavy isotope–labeled lauroyl-l-carnitine-(N,N,N-trimethyl-d9) 
(Sigma-Aldrich; carnitine treatment samples) was added to the 
homogenized sample to a final concentration of 50% methanol, and 
the sample was homogenized again at 25 Hz for 3 min. Homogenate 
was centrifuged for 15 min at 14,980g at 4°C. The centrifugation 
supernatant was collected and dried in a Savant SPD111V (Thermo 
Fisher Scientific) SpeedVac concentrator. The centrifugation pellet was 
resuspended in 3:1 (by volume) dichloromethane (Fisher Optima)–
to–methanol solvent mixture and further homogenized at 25 Hz for 
5 min, followed by centrifugation at 14,980g for 2 min. This latter 
centrifugation supernatant was collected and air-dried. Both extracts 
were stored at −80°C until LC-MS analysis.
Sample preparation for LC-MS/MS (plasma samples)
Samples from both replicates were analyzed jointly. Metabolite ex-
traction was performed by adding 20 l of plasma to 56 l of 100% 
high-performance LC (HPLC)–grade methanol spiked with 0.5 M 
sulfachloropyridazine (Sigma-Aldrich) and 0.5 M heavy isotope– 
labeled lauroyl-l-carnitine-(N,N,N-trimethyl-d9; Sigma-Aldrich) to 
a final concentration of 74% methanol. The samples were vortexed 
for 15 s and centrifuged at 14,980g for 15 min. The supernatant was 
collected and dried in a Savant SPD111V (Thermo Fisher Scientific) 
SpeedVac concentrator overnight.
Sample preparation for LC-MS/MS (cell culture samples)
C2C12 were infected at a 15:1 parasite–to–host cell ratio with luciferase- 
expressing T. cruzi strain CL Brener (3). Forty eight hours after in-
fection, cells were treated with 80 M carnitine or comparable volume 
of sterile water. Ninety-six hours after treatment, cultures were washed 
three times with ice-cold PBS, collected, snap-frozen, and stored at 
−80°C. Metabolites were extracted using 1:3:1 dichloromethane: 
methanol:H2O spiked with 2 M sulfachloropyridazine (Sigma- 
Aldrich) and analyzed by LC-MS/MS (four independent biological 
replicates analyzed in a single LC-MS/MS run; n = 4 per infection 
and treatment groups).
Liquid chromatography–tandem mass spectrometry
Dried tissue samples were resuspended in 50% methanol (Fisher Optima; 
LC-MS grade) spiked with 2 M sulfadimethoxine (Sigma-Aldrich) as 
internal control (except for heart samples, which were resuspended 
in 50% methanol), pooling aqueous and organic extracts together. 
Dried plasma samples were resuspended in 150 l of HPLC-grade 
water spiked with 0.5 M sulfadimethoxine as internal control. LC 
was performed using a Thermo Scientific Vanquish UHPLC system 
fitted with 1.7 m 100 Å Kinetex C8 column (50 × 2.1 mm) (Phe-
nomenex; GI tract and heart) or 1.6 m 100 Å Luna Omega Polar 
C18 column (50 × 2.1 mm) (Phenomenex; plasma samples and cell- 
culture samples), using water with 0.1% formic acid as mobile phase 
A and acetonitrile with 0.1% formic acid as mobile phase B. Data- 
dependent MS/MS experiments were performed on a Q Exactive Plus 
(Thermo Scientific) high-resolution MS, under the control of Xcalibur 
and Tune software (Thermo Scientific). Ions were generated for MS/
MS analysis in both positive and negative ion mode using heated 
electrospray ionization source. Calibration of the instrument was 
performed using recommended commercial calmix from Thermo 
Scientific. See table S2 for detailed instrumental parameters.
LC-MS/MS data analysis
Raw data were converted to mzXML format using MSConvert soft-
ware (25). Processing of the resulting mzXML files was done in 
MZmine versions 2.30 (GI tract), 2.33 (carnitine treatment tissue 
samples, except small intestine), 2.37 (carnitine treatment C2C12 
samples), and 2.51 (carnitine treatment small intestine samples) 
(see table S2 for parameters) (26). Data were filtered to only retain 
MS1 scans that were present in at least six samples (GI tract) or four 
samples (carnitine treatment samples) and were associated with 
MS2 spectra (and therefore could potentially be annotated). Blank 
removal was performed, with a minimum threefold difference 
between blank and samples required for a feature to be retained. 
Total ion current (TIC) normalization was performed in Jupyter 
Notebook using R (http://jupyter.org). PCoA was performed on the TIC- 
normalized MS1 data using the Bray-Curtis-Faith dissimilarity metric 
in QIIME 1 (27), visualized using EMPeror (28). PERMANOVA 
calculations were performed on Bray-Curtis-Faith distance matrices 
using the R package “vegan” (29). Samples close together in PCoA 
plot space indicate samples with similar metabolite profiles. Higher 
PERMANOVA R2 values indicate a greater relationship between the 
chemical variation and the selected metadata variable. Between-group 
average distance calculations were performed on the Bray-Curtis-
Faith dissimilarity matrix using categorized_dist_scatterplot.py in 
QIIME 1 (27). The GI tract model was built to scale from a picture 
of the GI tract collected from an additional uninfected C3H/HeJ 
mouse, using SketchUp 2017 software. Data were plotted onto this 
model using ‘ili (https://ili.embl.de/) (30). All ‘ili plots are scaled so 
that the lowest displayed abundance is assigned the coldest color 
and the highest abundance is assigned the warmest color. Individual 
scales are used for all plots, unless otherwise specified. Feature 
annotation was performed through molecular networking on the 
Global Natural Products Social Molecular Networking platform (31, 32) 
with the following parameters: pairs and library search minimum 
cosine, 0.7; precursor ion and fragment ion mass tolerance, 0.02 Da; 
four minimum matched peaks, TopK, 10; MS cluster enabled and min-
imum cluster size (for standard molecular networking workflow only), 
4; maximum component size, 100; minimum peak intensity, 0; filter 
below SD peak intensity, 0; filter precursor window and filter library; 
50-Da window filter; maximal mass shift, 100 Da (GI tract) or 500 Da 
(carnitine treatment experiments); row sum normalization (feature- 
based molecular networking only); aggregation method per group, 
sum (plasma) or mean (carnitine treatment experiments, tissue samples); 
and top results per query, 1 (feature-based molecular networking 
only). All annotations are levels 2 or 3 according to the metabolomics 
standards initiative (33). Molecular networks were visualized using Cyto-
scape (34). Venn diagrams were generated using http://bioinformatics.
psb.ugent.be/webtools/Venn/. Random forest classification (35) was 
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and 7501 trees. To determine the metabolic impact of carnitine 
treatment on plasma and heart, Kruskal-Wallis tests were used to 
compare median feature counts as a function of treatment. FDR- 
adjusted P < 0.05 was used to identify features with significant associa-
tions with treatments. In addition, for each feature, pairwise Wilcoxon 
tests were run to identify the specific category/categories showing 
significant differences in medians. A Bonferroni-adjusted P < 0.05 
was used to identify significant differences between each pair of 
treatments. A heat map was constructed using the “heat plot” func-
tion as implemented in the “made4” R package (36). Dendrograms 
are generated using unweighted pair group method with arithmetic 
mean clustering. Heat map colors depict normalized abundance 
determined from Z score calculations ([abundance − mean]/SD, 
between sample followed by within sample). Representative code can 
be accessed at https://github.com/mccall-lab-OU/GI-tract-paper.
16S method and data analysis
DNA was extracted from homogenized tissue samples using the 
DNeasy PowerSoil Kit (Qiagen) following the manufacturer’s protocols. 
Microbial load was determined using qPCR (FastStart Essential 
DNA Green kit, Roche) with primers (515F and 806R) targeting the 
16S ribosomal RNA (rRNA) gene. Samples were normalized on the 
basis of microbial load, and the V4 hypervariable region of the 16S 
rRNA gene was amplified using barcoded Illumina-compatible 
primers 515F and 806R as previously described (37). The resulting 
amplicons were pooled in equimolar proportions and sequenced on 
an Illumina MiSeq Instrument. Paired-end sequencing reads were 
quality-filtered and merged to reconstruct the complete V4 region 
using AdapterRemoval version 2 (38). These analysis-ready reads 
were used to identify operational taxonomic units (OTUs) follow-
ing the UNOISE pipeline implemented in USEARCH version 10 
(39). Taxonomy was assigned to the representative OTUs using the 
EzTaxon database (40). The resulting OTU table was rarefied to a 
depth of 5000 reads per individual, and all downstream statistical 
analyses were performed using this rarefied OTU table. Analyses of 
microbial community richness (alpha diversity quantified as observed 
species) and community composition [beta diversity quantified as 
unweighted UniFrac (41)] analyses were performed using scripts 
implemented in QIIME 1 (27). Kruskal-Wallis tests with FDR cor-
rection were used for comparison of genus-level taxonomic sum-
maries to infection status and disease stage.
Quantitative RT-PCR
RNAlater-preserved tissue from the heart base was homogenized 
for 6  min with 5-mm stainless steel beads in DNA/RNA shield 
(Zymo Research) and RNA extracted using the Quick-DNA/RNA 
MiniPrep Plus Kit (Zymo Research). mRNA was reverse-transcribed 
into cDNA (Invitrogen High-Capacity cDNA Reverse Transcription 
Kit with RNase Inhibitor), and the cDNA was used for qRT-PCR 
using the following primers: GACTTCAACAGCAACTCCCAC and 
TCCACCACCCTGTTGCTGTA (Gapdh), CCTGGTAAAGATG-
GTGCC and CACCAGGTTCACCTTTCGCACC (collagen I), and 
AAGTCCTAGCCAGTCTCCAGA and GAGCTGTCTCTGGGC-
CATTTC (Bnp) (42). Changes in gene expression were analyzed 
using the CT method.
Cardiac cytokine analysis
Heart base homogenate was analyzed using the Q-Plex Mouse 
Cytokine Screen (16-plex; Quansys Biosciences), according to 
manufacturers’ protocol and as previously described (6). Data were 
processed using Q-View software. Values below the limit of detec-
tion (LOD) of the kit for each cytokine were replaced with the LOD.
Statistical analysis
All statistical tests are paired. Nonparametric tests were used where 
possible (Mann-Whitney U test and Kruskal-Wallis test with Dunn’s 
post hoc test with Bonferroni correction), which make no assumptions 
as to data normality. No additional tests of normality were performed. 
For acylcarnitine data analysis and Fig. 2, where Mann-Whitney U 
tests were performed for each sampling site, FDR correction was 
performed to adjust for multiple comparison, as specified in the text 
and in the figure legends. Box plots display first quartile, median, 
and third quartile, with whiskers no more than 1.5 times the inter-
quartile range.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/30/eaaz2015/DC1
View/request a protocol for this paper from Bio-protocol.
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MSV000082614 (positive mode, esophagus), MSV000082615 (negative mode, esophagus), 
MSV000082618 (positive mode, stomach), MSV000082619 (negative mode, stomach), 
MSV000082612 (positive mode, small intestine), MSV000082613 (negative mode, small 
intestine), MSV000082616 (positive mode, large intestine and cecum), MSV000082617 
(negative mode, large intestine and cecum), MSV000084016 (carnitine treatment plasma 
analysis), MSV000083665 (carnitine treatment heart analysis), MSV000084325 (carnitine 
treatment, esophagus analysis), MSV000084297 (carnitine treatment, small intestine analysis), 
MSV000083111 (C2C12 carnitine treatment), and MSV000085142 (carnitine treatment, large 
intestine analysis)]. 16S data have been deposited in the NIH Short Read Archive (project 
number PRJNA553060). Molecular networks can be accessed here: https://gnps.ucsd.edu/
ProteoSAFe/status.jsp?task=801f2cc53c504fad8e64a08565173309# (positive mode 
networking from mzXML files; used for annotations and dataset matching), https://gnps.ucsd.
edu/ProteoSAFe/status.jsp?task=e46a139901094b63af54cb0e8371d164 (m/z 329.268 RT 3.02 
spectral matching; no 50-Da window filter), https://gnps.ucsd.edu/ProteoSAFe/status.
jsp?task=9480227e00ce42b385ab5a509aa57f81 (m/z 357.278 RT 2.88-min spectral  
matching; no 50-Da window filter), https://gnps.ucsd.edu/ProteoSAFe/ 
status.jsp?task=b3dd83cc7874499f834a30c5c475d90d (m/z 279.231 RT 2.97-min spectral 
matching; no 50-Da window filter), https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=688054
96317a45d19d8227d9ce751eb5 (m/z 293.247 RT 3.15-min spectral matching;  
no 50-Da window filter), https://gnps.ucsd.edu/ProteoSAFe/status.
jsp?task=4592e7dfd96c440f8885fb312d50e124 (positive mode feature-based molecular 
networking; used to cluster MS1 data into chemical families), https://gnps.ucsd.edu/
ProteoSAFe/status.jsp?task=d86b3d7c69c646479ef2cf5e7a432ba8 (negative mode 
networking from mzXML files; used for annotations and dataset matching), https://gnps.ucsd.
edu/ProteoSAFe/status.jsp?task=a6415577c1c24bc3823c9af5d9b5092c (negative mode 
feature-based molecular networking; used to cluster MS1 data into chemical families), https://
gnps.ucsd.edu/ProteoSAFe/status.jsp?task=f3119aeae8ab43f2bf2614e75c36c6f7 (plasma 
samples from carnitine treatment experiments), https://gnps.ucsd.edu/ProteoSAFe/status.
jsp?task=c06ea679a5354803b2be067b8d3c1ed2 (heart samples from carnitine  
treatment experiments), https://gnps.ucsd.edu/ProteoSAFe/status.
jsp?task=8f98f1ffaa004b1e9d86347f41bf6132 (esophagus samples from carnitine  
treatment experiments), https://gnps.ucsd.edu/ProteoSAFe/status.
jsp?task=57c502cc321d49ea89c42be899342420 (small intestine samples from carnitine 
treatment experiments), and https://gnps.ucsd.edu/ProteoSAFe/status.
jsp?task=bcc18b721bc44d5ba957a002451f31bc (large intestine samples from  
carnitine treatment experiments). Interactive spatial maps of metabolomic data for 
representative animals can be accessed here: https://ili.embl.de/?ftp://massive.ucsd.edu/
MSV000082614/updates/2019-07-10_ehossain_cee84dec/other/3D model of mouse 2_ili.
stl;ftp://massive.ucsd.edu/MSV000082614/updates/2019-07-10_ehossain_cee84dec/other/
Pos_m10_ili.csv (mouse 10, infected, acute-stage sample collection) and https://ili.embl.
de/?ftp://massive.ucsd.edu/MSV000082614/updates/2019-07-10_ehossain_cee84dec/
other/3D model of mouse 2_ili.stl;ftp://massive.ucsd.edu/MSV000082614/
updates/2019-07-10_ehossain_cee84dec/other/pos_m18_ili.csv (mouse 18, uninfected,  
89 days post-infection sample collection). All code can be accessed at https://github.com/
mccall-lab-OU/GI-tract-paper.
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